Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis - Test2 - elhamkhani - TriplyDB

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q28240230

about

Ambulatory and short-burst oxygen for interstitial lung disease Asbestosis and environmental causes of usual interstitial pneumonia Ambulatory and short-burst oxygen for interstitial lung disease Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Exercise training in idiopathic pulmonary fibrosis: is it of benefit?Therapeutic Approach to Adult Fibrotic Lung Diseases Recent advances in understanding idiopathic pulmonary fibrosis Nintedanib Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis Cardiac manifestations of idiopathic pulmonary fibrosis Pharmacological management of IPF Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis New perspectives on management of idiopathic pulmonary fibrosis Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Role and New Insights of Pirfenidone in Fibrotic Diseases Lung transplantation in IIP: A review Profile of nintedanib in the treatment of solid tumors: the evidence to date Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications Acute and subacute idiopathic interstitial pneumonias Ten things you should know about protein kinases: IUPHAR Review 14 Ovarian cancer standard of care: are there real alternatives?Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers IPF clinical trial design and endpoints Interstitial lung disease: raising the index of suspicion in primary care Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Open-access biorepository for idiopathic pulmonary fibrosis. The way forward Mechanisms of alveolar epithelial injury, repair, and fibrosis Smoking-related interstitial lung disease Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis.Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis

P2860

Q24187647-2EF72DBC-E889-4A4D-BE7F-E0D69EE7CEAA Q26159097-5815B924-3F51-4A1A-8749-B8CF656886C6 Q26471157-F80B20C4-4BDB-444D-84A0-33E176655DF2 Q26738458-2728A399-AC36-4111-AFBD-C4E8DAC0B700 Q26740857-770B3C14-7533-43DA-A255-F44AD25985BB Q26741569-3A03A2D4-1C14-408A-BEBE-C410E185F317 Q26745905-C0AE849D-2B4B-4408-8BE9-1DA2ECA6151C Q26747349-BC8A0F1B-BAC6-47BD-969D-64B9EA739290 Q26747694-14CDF15F-5735-4A87-B271-A88135F555A0 Q26748176-E419283B-27C4-4749-9B07-CA92E8202BA1 Q26748808-5A9F4612-8F6E-4059-8DE8-D2BD6DD2117E Q26750418-6E8E4212-5363-424B-BA2C-0D02759C4E3E Q26765586-6BB00939-3EB0-4EB2-86B4-48C9AAADEA5E Q26766313-4BCE6A16-E4AF-4798-8402-91D10F7056AA Q26770376-6F80BD0A-BD91-4A4F-BA28-769ADD4549FF Q26771309-B3A86181-1C42-4491-A641-630D00EC1838 Q26771647-F955844B-08B5-47CF-90C4-D33FBCE311FB Q26773161-6A4FC7BF-D4AF-4A12-BE29-155FEAF84A1E Q26774154-002B7F12-2AB1-4DA0-ACC7-EE6C6BA20C14 Q26774870-6B5BA674-6768-4EDC-8ED5-81C34DFE4E9D Q26775134-8E2B1475-4F6C-479E-A581-1993DC06A24D Q26775753-3679C3FD-F85D-4941-A358-346771CD41ED Q26776473-8B8055A5-31C3-4E8B-BFEA-F1DD2B3D9988 Q26777928-69AE10A2-B46B-4132-80BB-64270BF738FA Q26781255-7EF95A93-3BC8-47A3-AC33-31F1D9B72880 Q26783169-35428830-6FD9-417C-9677-A2A0849C016B Q26801718-6F032307-76BB-4DC3-BBD3-01C31118605E Q26824327-CC493650-D2D2-4F0C-8399-49D7FF871DB8 Q26849417-15D1D9FA-F178-4D8E-88F3-14656BAD9A94 Q26862249-CFBD170E-839A-43E7-AAEC-0079B521171E Q26864836-BEC646F1-0303-4407-887F-0D65A00C6FC8 Q26995648-8B322285-FAA1-4912-9E40-CCAED1178855 Q27001028-6649CCB5-68BF-4911-9814-249BB036E7E9 Q27001560-C0C783D3-29B4-448A-BE81-D3D181D3B929 Q27003322-26D4ED76-BDC1-4272-8871-E4A8E32A76D0 Q27023971-AAC21EF3-ADD1-426D-8123-E7BADBCF7D97 Q27027779-D6FF7758-7FE6-41F8-A78F-D1EB03CB0995 Q27309696-A22BA626-6963-4340-AC4A-341BFB0F762B Q27309770-E1C61CF9-ED00-4621-B058-F56DE87B2E3B Q27333960-1D7F07EA-19DC-4507-998A-483387198926

P2860

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q28240230

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@ast

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@en

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@nl

type

label

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@ast

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@en

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@nl

prefLabel

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@ast

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@en

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@nl

P1433

Q28240230-2874B468-D1F8-44BA-ABEE-EB69FA5728BC

P1476

Q28240230-EC7F46EB-1B03-4CAE-BB73-CB980F6ED474

P2093

Q28240230-1B651C92-C5AF-41CD-A2AA-AB457F97B0A8

Q28240230-1CA6D289-113F-4A92-8074-ACE6292D6D1A

Q28240230-1CD38038-BBC4-4ED1-8687-50F4D8D34377

Q28240230-1D45D200-E461-49E9-956C-2A97A6E4BF2B

Q28240230-305FF938-2F40-4C56-974B-2AF6BA360AE5

Q28240230-3A2B209E-709D-48C2-B7F5-C0C392894CA0

Q28240230-50C7F201-C742-4D31-A897-0B149ADD0A3E

Q28240230-54E68206-5A7D-457D-A320-18CBAE640FB3

Q28240230-566731A4-DCFA-4F08-8B6C-E3416E9F5081

Q28240230-5DA1C55C-1B1C-4956-A0C9-6D84617EDAFB

P304

Q28240230-E84CC614-E7A4-4C05-A79A-2682F3B579F8

P31

Q28240230-E0BB8B81-5FEB-4C52-A62C-BA504DC56D7C

P3181

Q28240230-47F5248C-E901-4098-8254-72B8C20969FE

P356

Q28240230-EA35FBE1-27F3-4B3A-AF38-E12BB935756E

P407

Q28240230-031028CC-799B-413D-9AF3-D0DFC493AA37

P433

Q28240230-FF18EA2A-F665-464A-9FFA-5D49F6028353

P478

Q28240230-F7024BF3-D0DC-4CA8-9CD2-A88853F21E90

P50

Q28240230-22027858-816F-4D66-A10B-8F3F53F7C2D5

Q28240230-AE14796A-7D4D-41AB-856F-8137E7812F85

Q28240230-E704083A-3310-44E5-8D27-D122D6B0D3A9

P577

Q28240230-54D873A7-62A8-4590-956D-60FA2A71FFB7

P698

Q28240230-CB144259-DB8E-4074-8502-BABFD6326A29

P921

Q28240230-2C260784-0C8F-4CA9-8D69-A27C4D77F574

Q28240230-E53EA48F-7BB8-4414-9624-7C4616826D10

P3181

P356

P1433

The New England Journal of Medicine

P1476

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

@en

P2093

Andrew G Nicholson

http://www.w3.org/2001/XMLSchema#string

Bernd Disse

http://www.w3.org/2001/XMLSchema#string

David M Hansell

http://www.w3.org/2001/XMLSchema#string

Dong Soon Kim

http://www.w3.org/2001/XMLSchema#string

Florence Le Maulf

http://www.w3.org/2001/XMLSchema#string

Ganesh Raghu

http://www.w3.org/2001/XMLSchema#string

Harold R Collard

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Taniguchi

http://www.w3.org/2001/XMLSchema#string

INPULSIS Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Kevin K Brown

http://www.w3.org/2001/XMLSchema#string

P304

2071-2082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

10803

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1402584

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Ulrich Costabel

P577

2014-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24836310

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis